Chondroitin sulfatase, identified by the CAS number 9025-60-9, is an enzyme that plays a crucial role in the degradation of glycosaminoglycans, particularly chondroitin sulfate. This enzyme catalyzes the hydrolysis of sulfate esters in chondroitin sulfate, facilitating its breakdown into smaller oligosaccharides. Chondroitin sulfatase is typically produced by certain bacteria and is involved in various biological processes, including tissue remodeling and the regulation of extracellular matrix components. It is characterized by its specificity for sulfate groups and its ability to act under physiological conditions. The enzyme is of interest in biomedical research, particularly in the context of cartilage degradation and diseases such as osteoarthritis, where the modulation of glycosaminoglycan metabolism may have therapeutic implications. Additionally, chondroitin sulfatase is studied for its potential applications in biotechnology and drug development, particularly in the design of enzyme-based therapies for conditions involving connective tissue disorders.

Chondroitin sulfatase

9025-60-9: Chondroitin sulfatase, identified by the CAS number 9025-60-9, is an enzyme that plays a crucial role in the degradation of glycosaminoglycans, particularly chondroitin sulfate. This enzyme catalyzes the hydrolysis of sulfate esters in chondroitin sulfate, facilitating its breakdown into smaller oligosaccharides. Chondroitin sulfatase is typically produced by certain bacteria and is involved in various biological processes, including tissue remodeling and the regulation of extracellular matrix components. It is characterized by its specificity for sulfate groups and its ability to act under physiological conditions. The enzyme is of interest in biomedical research, particularly in the context of cartilage degradation and diseases such as osteoarthritis, where the modulation of glycosaminoglycan metabolism may have therapeutic implications. Additionally, chondroitin sulfatase is studied for its potential applications in biotechnology and drug development, particularly in the design of enzyme-based therapies for conditions involving connective tissue disorders.

<p>Elosulfase alfa (BMN 110), a recombinant human N-acetylgalactosamine-6-sulfatase (GALNS), serves as enzyme replacement therapy for mucopolysaccharidosis IVA (</p>

CAS 9025-60-9

Chondroitin sulfatase

Elosulfase alfa

Ref: TM-T82477